Table 1.

Clinical and Imaging Characteristics at Admission and Follow-Up in 11 Patients With Post–COVID-19 Vaccine Associated Myopericarditis

Case	Age, Race, and Sex	Vaccine	Time From Vaccine to Presentation	Symptoms at Admission	CMR Findings at Admission	LVEF and RVEF at Admissiona	Symptoms at Follow-Up	CMR Findings at Follow-Up	LVEF and RVEF at Follow-Up
1	21-year-old White man	BNT162b2	24 h	Pericarditic substernal chest pain	Edema. Focal epicardial enhancement. Thickening and enhancement of the pericardium.	53% and 44%	4 mo: asymptomatic	Not available	Not available
2	16-year-old Black man	BNT162b2	48 h	Fever, fatigue, headache, dyspnea, pericarditic substernal chest pain	Diffuse, patchy edema. Focal subepicardial to near-transmural enhancement. Hyperintense pericardial signal.	57% and 47%	3 mo: intermittent dyspnea and chest discomfort with exertion	2 mo: no edema; continued enhancement, but with improved intensity and thickness; unchanged pericardial signal	54% and 49%
3	17-year-old White man	BNT162b2	72 h	Fever, headache, myalgias, pericarditic substernal chest pain	No edema. Focal epicardial delayed enhancement. Thickening and enhancement of the pericardium.	58% and 50%	4 mo: asymptomatic	2 mo: no edema; continued enhanced, but improved thickness; unchanged pericardial findings	62% and 51%
4	28-year-old Black man	mRNA-1273	24 h	Fever, chills, nausea, lethargy, palpitations, chest pain, back pain	Patchy edema. Focal epicardial delayed enhancement. No pericardial abnormalities.	55% and 48%	1 mo: asymptomatic	Not available	Not available
5	18-year-old White man	BNT162b2	24 h	Fever, headache, myalgias, chest pain radiating to left shoulder	Localized edema. Focal, linear delayed epicardial enhancement. Hyperintense pericardial signal and thickened pericardium.	56% and 49%	4 mo: asymptomatic	4 mo: no edema; improved enhancement; mildly thickened pericardium	56% and 50%
6	38-year-old White woman	BNT162b2	24 h	Fever, myalgias, dyspnea, pericarditic substernal chest pain	No edema. Focal delayed mid-myocardial enhancement. No pericardial changes, but trace pericardial effusion.	62% and 62%	2 mo: asymptomatic	3 mo: no edema; near-complete resolution of enhancement; resolution of pericardial effusion	59% and 58%
7	23-year-old Black man	BNT162b2	12 d	Epigastric pain, nausea, chest pain	No edema. Linear mid-myocardial delayed enhancement. No pericardial changes.	62% and 53%	2 mo: asymptomatic	Not available	Not available
8	53-year-old White man	Ad26.COV2.S	8 d	Weakness, myalgias, chest pain	No edema. Focal subepicardial enhancement. Diffuse pericardial enhancement and mild thickening. Small pericardial effusion.	70% and 51%	2 mo: asymptomatic	Not available	Not available
9	19-year-old White man	BNT162b2	36 h	Fever, headache, pericarditic substernal chest pain	No edema. Negative enhancement. Bright and prominent pericardium with trivial pericardial effusion.	60% and 53%	2 mo: intermittent palpitations and sharp chest pain	3 mo: focal subepicardial enhancement; unchanged pericardial findings	56% and 49%
10	17-year-old White man	BNT162b2	36 h	Fever, chills, fatigue, myalgias, pericarditic substernal chest pain	No edema. Focal mid-myocardial and epicardial delayed enhancement. No pericardial changes.	61% and 59%	4 mo: asymptomatic	4 mo: no edema; mild improvement in enhancement; hyperintense pericardial signal and thickened pericardium; trivial pericardial effusion	57% and 53%
11	19-year-old White man	BNT162b2	72 h	Palpitations, pericarditic substernal chest pain	No edema. Focal mid-myocardial and near-transmural delayed enhancement. No pericardial changes. Hyperintense pericardial signal and thickened pericardium.	59% and 54%	4 mo: asymptomatic	4 mo: no edema; mild focal improvement in enhancement; hyperintense pericardial signal and thickened pericardium; trivial pericardial effusion	56% and 58%

CMR = cardiac magnetic resonance; LVEF = left ventricular ejection fraction; RVEF = right ventricular ejection fraction.

^aLVEF and RVEF were measured via CMR.